+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 13 Actively Recruiting clinical trials

S

Actively Recruiting

This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.

Age: 18Years +All GendersPhase 3
771 locations
C

Actively Recruiting

Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.

Age: 18Years +All GendersPhase 3
303 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of brenipatide, given alongside standard of care, compared with a placebo plus standard of care, in delaying the worsening of symptoms in adults with bipolar disorder. This phase 2, randomized, double-blind study aims to better understand how brenipatide might help manage bipolar disorder symptoms over time. Participants receive either one of two doses of brenipatide or a placebo, both administered by subcutaneous injection, combined with their standard bipolar disorder treatment. The study includes three main periods a screening period lasting about one month, a treatment period lasting at least six months, and a follow-up period of about two months. Study participation may be shortened if symptoms worsen or if the participant chooses to withdraw. During the study, participants are asked to self-inject the study medication, keep electronic and paper diaries, and complete questionnaires. Researchers will monitor outcomes such as time to relapse, changes in disability, depression and mania scores, quality of life, patient impressions, body weight changes, and treatment-related antibody development. Safety and effectiveness measures will be collected throughout treatment and follow-up, with total participation lasting around nine months or less depending on individual circumstances.

Age: 18Years - 75YearsAll GendersPhase 2
87 locations
L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.

Age: 18Years - 65YearsAll GendersPhase 3
184 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of adding KarXT to existing treatments for mania in adults with Bipolar-I Disorder. This trial focuses on participants experiencing an acute manic episode, with or without mixed features, who are already taking lithium, valproate, or lamotrigine. The study aims to improve mania symptoms, measured by changes in the Young Mania Rating Scale after five weeks. Participants will be randomly assigned to receive either KarXT in addition to their mood stabilizer or a placebo plus their mood stabilizer. The treatments are given in specified doses over the study period, with careful monitoring of side effects and other health measures. The study includes a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants will undergo regular assessments including psychiatric evaluations, rating scales for mania and other symptoms, and safety monitoring up to seven weeks. Researchers will track symptom changes, treatment responses, and any adverse events. Participants are involved in scheduled visits for evaluations and to maintain stable mood stabilizer doses. The total participation lasts until the primary outcome is measured at week five, with additional safety follow-up up to week seven.

Age: 18Years - 65YearsAll GendersPhase 3
109 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of KarXT for treating manic episodes in adults with Bipolar-I Disorder. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults experiencing an acute episode of mania or mania with mixed features. The study aims to compare KarXT to placebo during a 3-week inpatient treatment period to assess symptom improvement. Participants will be randomly assigned to receive either KarXT or a placebo with flexible dosing during the 3-week inpatient phase. Prior to treatment, participants must undergo a screening period and psychotropic medications must be washed out within 14 days before starting. After the treatment phase, there is a safety follow-up period, with the entire study lasting no more than seven weeks. During the study, participants will be hospitalized for close monitoring. Researchers will assess symptoms using the Young Mania Rating Scale and Clinical Global Impressions-Bipolar at baseline and week 3. Safety evaluations will continue through follow-up visits. The main outcome is the change in mania symptoms after 3 weeks of treatment, with additional measures of clinical response and safety observed throughout the study.

Age: 18Years - 65YearsAll GendersPhase 3
74 locations
R

Actively Recruiting

Researchers are evaluating remibrutinib for its effectiveness and safety in treating patients with secondary progressive multiple sclerosis SPMS. This Phase III, randomized, double-blind, placebo-controlled study involves about 1275 participants who meet specific criteria, including an SPMS diagnosis and disability progression. The trial is designed to provide detailed data on remibrutinibs impact compared to placebo, with a focus on disability progression and other neurological measures. Participants are randomly assigned to receive either remibrutinib or a matching placebo tablet during the Core Part of the study, which is event-driven and double-blind. Following this, there is an Extension Part where all participants receive open-label remibrutinib tablets. Treatment is oral and involves ongoing monitoring to assess long-term effects and safety. Throughout the study, participants will undergo regular assessments including disability evaluations using the Expanded Disability Status Scale EDSS, Timed 25-Foot Walk, 9-Hole Peg Test, and cognitive testing with the Symbol Digit Modalities Test SDMT. Brain imaging will be used to track lesion development and brain atrophy. Safety will be closely monitored by recording adverse events. The total participation may span up to approximately five years, covering both core and extension phases.

Age: 18Years - 65YearsAll GendersPhase 3
296 locations
L

Actively Recruiting

Researchers are studying the long-term safety and effectiveness of pembrolizumab MK-3475 in participants with advanced tumors or blood cancers who were part of previous pembrolizumab-based studies. This extension study includes participants currently receiving treatment or in follow-up from parent trials. It consists of three phases the First Course Phase, Survival Follow-up Phase, and Second Course Phase, depending on the participants status at the end of their previous study. Participants may receive pembrolizumab alone or combined with standard of care treatments, lenvatinib, or other study drugs like olaparib and MK-4280, delivered mainly by intravenous infusion or oral capsules. Dosing schedules vary, including pembrolizumab administered every 3 or 6 weeks for up to 35 or 17 doses depending on the phase. Some participants may take lenvatinib orally daily, timed with pembrolizumab infusions, while others may receive investigational combination therapies or standard care treatments according to their parent studys protocol. During the study, participants will have regular infusions or oral dosing and be monitored over several years for overall survival and other outcomes like progression-free survival and adverse events. Researchers will assess safety and efficacy for up to approximately 10 years, with detailed tracking of side effects and treatment discontinuations. Study visits and assessments will be conducted to evaluate organ function, disease status, and any treatment-related effects throughout the study duration.

Age: 18Years +All GendersPhase 3
782 locations
D

Actively Recruiting

Researchers are evaluating an organ dysfunction score adapted specifically for pregnant and early postpartum patients up to 3 days after birth admitted to intensive care units ICU. This observational study aims to determine if this adjusted score, called SOFA-OBS, better predicts ICU mortality compared to the general SOFA score. The study also assesses whether a non-invasive pulse oximeter can effectively evaluate respiratory function instead of the standard arterial blood gas test, which is more painful and invasive. The study involves following pregnant and postpartum patients admitted to the ICU for at least 24 hours. Researchers will collect routine clinical data and laboratory results already used in ICU care, without requiring extra interventions. The SOFA-OBS score adjusts kidney function and blood pressure measurements to reflect the physiological changes during pregnancy and postpartum. It also replaces arterial blood gas oxygen measurements with pulse oximetry when blood gas analysis is unavailable. Data will be recorded daily during the ICU stay. Participants will be monitored for organ dysfunction and mortality outcomes during their ICU stay or up to 28 days after enrollment. Researchers will evaluate and compare the predictive ability of the SOFA-OBS and general SOFA scores for ICU mortality and sepsis-related death. Data quality will be carefully checked, and privacy will be protected by anonymizing patient information. The study is approved by ethical boards and requires informed consent from participants, with a planned enrollment of 130 patients.

Age: 18Years +FEMALE
18 locations
E

Actively Recruiting

Researchers are evaluating how well seltorexant works and its safety when added to antidepressant treatment in adults and elderly participants with major depressive disorder who also experience insomnia symptoms. The study focuses on participants who have not adequately responded to treatment with selective serotonin reuptake inhibitors SSRIs or serotonin-norepinephrine reuptake inhibitors SNRIs. It aims to compare seltorexant with placebo as an additional therapy to improve depressive symptoms in this group. Participants will take seltorexant or a matching placebo orally once daily for 6 weeks during the double-blind phase of Part 1, while continuing their current SSRI or SNRI antidepressant. Those who complete Part 1 and meet criteria can enter Part 2, which includes open-label induction and stabilization phases where all receive seltorexant alongside their antidepressant. Participants who achieve a stable response then enter a double-blind maintenance phase in Part 2, receiving either seltorexant or placebo daily along with their antidepressant. During the study, participants will undergo assessments including depression rating scales like the Montgomery-Asberg Depression Rating Scale MADRS and patient-reported sleep disturbance measures. Researchers will monitor changes in depressive symptoms and sleep over time, track time to relapse during the maintenance phase, and evaluate safety. The total study duration may extend up to nearly three years for some participants, with follow-up after each treatment phase.

Age: 18Years - 74YearsAll GendersPhase 3
205 locations

1-10 of 13

1